Современные взгляды на использование анатомических и клинико-анатомических шкал, основанных на данных исследования SYNTAX, при выборе стратегии реваскуляризации миокарда

Лечение пациентов с трехсосудистым поражением коронарных артерий, согласно европейским и американским рекомендациям, включает чрескожное коронарное вмешательство или коронарное шунтирование. В зависимости от анатомической сложности поражения коронарных артерий с использованием шкалы SYNTAX score выбирают одну из стратегий лечения. Однако в последние годы в научной литературе активно обсуждают недостатки указанной шкалы, которая не полностью соответствует возможностям современной клинической практики. В обзоре освещены современные взгляды на анатомические и клинико-анатомические шкалы, которые позволяют выбрать оптимальный метод прямой реваскуляризации миокарда у больных с трехсосудистым поражением и/или поражением ствола левой коронарной артерии.

1. Всемирный атлас профилактики сердечнососудистых заболеваний и борьбы с ними. Женева: Всемирная организация здравоохранения; 2013.

2. Глобальный план действий по профилактике неинфекционных болезней и борьбе с ними на 2013– 2020 гг. Женева: Всемирная организация здравоохранения; 2014.

3. Чазова Е.И., Ощепкова Е.В. Борьба с сердечнососудистыми заболеваниями: проблемы и пути их решения на современном этапе. Вестник Росздравнадзора. 2015; N5: 7–10.

4. Wang W., Jiang B., Sun H., Ru X., Sun D., Wang L., Wang L., Jiang Y., Li Y., Wang Y., Chen Z., Wu S., Zhang Y., Wang D., Wang Y., Feigin V.L. NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide PopulationBased Survey of 480 687 Adults. Circulation. 2017

5. Алекян Б.Г., Григорьян А.М., Стаферов А.В., Карапетян Н.Г. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации – 2017 год. Эндоваскулярная хирургия. 2018; 5 (2): 93–240. DOI: 10.24183/2409-4080-2018-5-2-93-240

6. Бокерия Л.А., Милиевская Е.Б., Кудзоева З.Ф., Прянишников В.В., Скопин И.И., Юрлов И.А. «Сердечно-сосудистая хирургия - 2018. Болезни и врожденные аномалии системы кровообращения». Москва, ФГБУ «НМИЦССХ им. А.Н. Бакулева» МЗ РФ, 2019, 270 с.

7. Daemen J., Boersma E., Flather M., Booth J., Stables R., Rodriguez A. et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a metaanalysis with 5-year patient-level data from the ARTS, ERACIII, MASS-II, and SoS trials. Circulation. 2008; 118 (11): 1146–54. DOI: 10.1161/CIRCULATIONAHA.107.752147

8. Farooq V., Serruys P.W. “Cherry-picking” patients for randomized, controlled trials – reliving the past. J. Am. Coll. Cardiol. 2013; 61 (24): 2492. DOI: 10.1016/j.jacc.2013.03.018

9. Taggart D.P., Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. Ann. Thorac. Surg. 2006; 82 (6): 1966–75. DOI: 10.1016/j.athoracsur.2006.06.035

10. Soran O., Manchanda A., Schueler S. Percutaneous coronary intervention versus coronary artery bypass surgery in multivessel disease: a current perspective. Interact. Cardiovasc. Thorac. Surg. 2009; 8 (6): 666–71. DOI: 10.1510/icvts.2008.195644

11. Bravata D.M., Gienger A.L., McDonald K.M., Sundaram V., Perez M.V., Varghese R. et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann. Intern. Med. 2007; 147 (10): 703–16. DOI: 10.7326/0003-4819-147-10-200711200-00185

12. Patrick W. Serruys, MD, PhD, Marie-Claude Morice, MD, A. Pieter Kappetein, MD, PhD, Antonio Colombo, MD, David R. Holmes, MD, Michael J. Mack. Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med. 2009; 360:961–972.

13. Authors/Task Force members, Windecker S., Kolh P., Alfonso F., Collet J. P., Cremer J., J ni P. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for CardioThoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European heart journal. 2014. 35(37), 2541–2619. 135 (8): 759–771. Available at: doi: 10.1161/CIRCULATIONAHA.116.025250. (accessed 22.02.2019).

14. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Jüni P. ESC/EACTS Guidelines on myocardial revascularization. European heart journal. 2018.

15. Morice M.C., Serruys P.W., Kappetein A.P., Feldman T.E., St hle E., Colombo A., Religa G. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the SYNTAX trial. Circulation. 2014. CIRCULATIONAHA-113.

16. Iqbal J., Vergouwe Y., Bourantas C.V., Klaveren D.V., Zhang Y.J., Campos C.M., Steyerberg E.W. Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. JACC: Cardiovascular Interventions. 2014. 7(5), 464–470.

17. Farooq V., Brugaletta S., Serruys P.W. Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. Heart. 2011; 97 (23): 1902–13. DOI: 10.1136/heartjnl-2011-300718

18. Head S.J., Farooq V., Serruys P.W., Kappetein A.P. The SYNTAX score and its clinical implications. Heart. 2014; 100 (2): 169–77. DOI: 10.1136/heartjnl-2012-302482

19. Daniel J F M Thuijs, A Pieter Kappetein , Patrick W Serruys , Friedrich-Wilhelm Mohr , Marie-Claude Morice, Michael J Mack , David R Holmes Jr , Nick Curzen , Piroze Davierwala , Thilo Noack , Milan Milojevic, Keith D Dawkins, Bruno R da Costa , Peter Jüni, Stuart J Head, Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial Lancet. 2019 Oct 12;394(10206):1325-1334. doi: 10.1016/S0140-6736(19)31997-X. Epub 2019 Sep 2.

20. Farooq V., van Klaveren D., Steyerberg E.W., Meliga E., Vergouwe Y., Chieffo A. et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013; 381 (9867): 639–50. DOI: 10.1016/S0140-6736(13)60108-7

21. Hua Yang 1, Li Zhang 2, Chen Hong Xu 1 Use of the SYNTAX Score II to predict mortality in interventional cardiology: A systematic review and meta-analysis 2019 Jan;98(2):e14043. doi: 10.1097/MD.0000000000014043.

22. Ying Song 1, Changdong Guan 2, Xuebin Cao 3, Lei Qin 4, Yi Li 5, Zhanquan Li 6, Shaoping Nie 7, Shuang Hou 8, Min Zhang 8, Runlin Gao 1, Jinqing Yuan 9, Bo Xu 10, PANDA III Investigators Validation of the long-term prognostic capability of the SYNTAX score II in patients undergoing biodegradable polymer-based Sirolimus-eluting stents: 2-year outcomes from the PANDA III trial Int J Cardiol . 2020 Jun 15;309:27-32. doi: 10.1016/j.ijcard.2020.02.042. Epub 2020 Feb 15.

23. Guofeng Gao 1, Yanyan Zhao 1, Dong Zhang 1, Yuan He 1, Chenxi Song 1, Chenggang Zhu 1, Changdong Guan 1, Bo Xu 1, Dong Yin 1, Kefei Dou 1 Is the SYNTAX Score II applicable in all percutaneous coronary intervention patients?

24. Maxime M Vroegindewey 1, Anne-Sophie Schuurman 1, Rohit M Oemrawsingh 1 2, Robert-Jan van Geuns 1, Isabella Kardys 1, Jurgen Ligthart 1, Joost Daemen 1, Eric Boersma 1, Patrick W Serruys 1 3, K Martijn Akkerhuis 1 SYNTAX score II predicts long-term mortality in patients with one- or twovessel disease

25. Sorin J Brener 1, Venkatesh Alapati, Doris Chan, Akanibo Da-Wariboko, Yousef Kaid, Yevgeniy Latyshev, Amr Moussa, Chockalingham A Narayanan, John P O'Laughlin, Amol Raizada, Gautam Verma, Terrence J Sacchi The SYNTAX II Score Predicts Mortality at 4 Years in Patients Undergoing Percutaneous Coronary Intervention

26. Jeehoon Kang 1, Jung Kyu Han 2, Do Yoon Kang 1, Chengbin Zheng 1, Han Mo Yang 1, Kyung Woo Park 1, Hyun Jae Kang 1, Bon Kwon Koo 1, Hyo Soo Kim 1 SYNTAX Score and SYNTAX Score II Can Predict the Clinical Outcomes of Patients with Left Main and/or 3-Vessel Disease Undergoing Percutaneous Coronary Intervention in the Contemporary CobaltChromium Everolimus-Eluting Stent Era Korean Circ J 2020 Jan;50(1):22-34. doi: 10.4070/kcj.2019.0097. Epub 2019 Sep 30.

27. Enrico Cerrato 1, Umberto Barbero 2 3, Giorgio Quadri 1, Nicola Ryan 4, Fabrizio D'Ascenzo 5, Francesco Tomassini 1, Alicia Quirós 6, Simone Bellucca 1, Federico Conrotto 5, Fabrizio Ugo 7, Hiroyoshi Kawamoto 8, Cristina Rolfo 1, Marco Pavani 9, Hernan Mejia-Renteria 4, Sebastiano Gili 10, Mario Iannaccone 2, Michele Debenedictis 2, Doronzo Baldassarre 2, Giuseppe Biondi-Zoccai 11 12, Antonio Colombo 8, Ferdinando Varbella 1, Javier Escaned 4 Prediction of longterm patient outcome after contemporary left main stenting using the SYNTAX and SYNTAX II scores: A comparative analysis from the FAIL-II multicenter registry (failure in left main study with 2nd generation stents-Cardiogroup III study) Catheter Cardiovasc Interv 2020 Jul;96(1):E17-E26. doi: 10.1002/ccd.28468. Epub 2019 Sep 2.

28. Geoffrey J Yanes Bowden 1, Francisco Bosa Ojeda 1, Alejandro Jiménez Sosa 2, Alejandro Sánchez-Grande Flecha 1, Corabel Méndez Vargas 1, Miguel Leiva Gordillo 1, Julio Miranda Bacallado 1 Prognostic value of SYNTAX score and SYNTAX score II in an 'all-comers' population treated with angoplasty

29. Patrick W Serruys 1, Norihiro Kogame, Yuki Katagiri, Rodrigo Modolo, Pawel E Buszman, Andrés Íñiguez-Romo, Javier Goicolea, David Hildick-Smith, Andrzej Ochala, Dariusz Dudek, Jan J Piek, Joanna J Wykrzykowska, Javier Escaned, Adrian P Banning, Vasim Farooq, Yoshinobu Onuma Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: two-year follow-up of the SYNTAX II study

30. Kuniaki Takahashi 1, Patrick W Serruys 2, Valentin Fuster 3, Michael E Farkouh 4, J ohn A Spertus 5, David J Cohen 6, Seung-Jung Park 7, Duk-Woo Park 7, Jung-Min Ahn 7, Arie Pieter Kappetein 8, Stuart J Head 8, Daniel Jfm Thuijs 8, Yoshinobu Onuma 9, David M Kent 10, Ewout W Steyerberg 11, David van Klaveren 12, SYNTAXES, FREEDOM, BEST, and PRECOMBAT trial investigators. Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation Lancet 2020 Oct 31;396(10260):1399-1412. doi: 10.1016/S0140-6736(20)32114-0. Epub 2020 Oct 8.

31. Алекян Б.Г., Карапетян Н.Г., Кишмирян Д.О., Ревишвили А.Ш. Эффективность использования шкалы риска SYNTAX Score II при выборе стратегии реваскуляризации миокарда у пациентов с трехсосудистым поражением венечных артерий и ствола левой коронарной артерии. Эндоваскулярная хирургия. 2020; 7 (4): 334–44. DOI: 10.24183/2409-4080-2020-7-4-334-344